

GMP production of targeted therapeutic bacteriophages for the treatment of incurable hospital-acquired infections

BRC-Bio Ltd. is launching an innovative project to develop GMP (Good Manufacturing Practice) manufacturing of targeted therapeutic bacteriophage products for the treatment of incurable hospital-acquired infections, with a total of HUF 243 million in funding from the National Research, Development and Innovation Office.

Antibiotic resistance is one of the most serious public health challenges of our time, leading to tens of thousands of deaths in Europe and the United States every year. One of the most promising alternatives to effectively treat bacterial infections resistant to conventional antibiotic treatments is bacteriophage therapy - the use of bacteriophages that target and kill bacteria

Unique challenge, unique solution

One of the main challenges of bacteriophage therapy is the need to target different strains of bacteria with a specific formulation of bacteriophage preparations, which take months to produce. This is a major barrier to treating life-threatening infections that progress rapidly.

Innovative technology for faster therapy

BRC-Bio Ltd. aims to solve this problem by further developing a patented biotechnology process developed at the HUN-REN Biological Research Centre Szeged. The technology allows the availability of the right bacteriophage preparation almost immediately after the diagnosis of a hospital-acquired infection.

The development focuses on two priority, health-critical bacteria types for which no current antibiotic is often effective and the rapid progression of infection requires immediate intervention.

Pharmaceutical-grade manufacturing and European target

The project will develop a pharmaceutical-grade manufacturing process that meets European standards and allows the production of targeted bacteriophage formulations.

Laying the foundations for domestic bacteriophage therapy

The project aims not only to meet market needs, but also has a long-term mission: to lay the foundations for the domestic use of bacteriophage therapy and open up new opportunities for the effective treatment of antibiotic-resistant hospital-acquired infections.



2023-1.1.2-GYORSÍTÓSAV-2024-00011

Project title: GMP production of targeted therapeutic bacteriophage products for the treatment of incurable hospital-acquired infections

Project ID number: 2023-1.1.2-GYORSÍTÓSAV-2024-00011

Project duration: 2025.01.01-2027.12.31.

Project budget: 338 094 901 HUF

Contracted amount of funding: 243 020 616 HUF

Rate of funding: 71,87%

Beneficiary name: BRC Bio Ltd.

Contact person: Dr. Endre Kiss-Tóth, endre.kiss-toth@brc-bio.com, 06 20 467 5362,

Webpage: <https://brc-bio.com/>



NATIONAL RESEARCH, DEVELOPMENT
AND INNOVATION OFFICE
HUNGARY

PROJECT
FINANCED FROM
THE NRDI FUND